CTOs on the Move


 
Salix is committed to being the leading US specialty pharmaceutical company licensing, developing, and marketing innovative products to healthcare professionals to treat gastrointestinal disorders in patients.
  • Number of Employees: 100-250
  • Annual Revenue: $250-500 Million
  • www.salix.com
  • 8510 Colonnade Center Dr
    Raleigh, NC USA 27615
  • Phone: 919.862.1000

Executives

Name Title Contact Details

Similar Companies

Cloud Pharmaceuticals

Cloud Pharmaceuticals is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. The company accelerates the drug discovery and design process in a way that delivers tangible results and true value for its partners.

HatchMed

HatchMed - Bringing user centric design into the medical equipment world https://t.co/7vuyMSBnct #hospital #nurseproof #Seattle

Mirum Pharmaceuticals

Mirum Pharmaceuticals (NASDAQ: MIRM) is dedicated to creating life-changing therapies for patients with liver diseases. We are advancing our lead product candidate for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) — conditions with a profound and devastating impact on quality of life for young patients and their families. Untreated, these conditions can lead to liver failure and inflict life-altering symptoms including stunted growth and severe, non-stop itching. Under current standard of care, patients often require a liver transplant and are at higher risk of many serious health issues. Working closely with patients and caregiver communities, we intimately understand the challenges of living with cholestatic liver diseases. Based on a wealth of data from clinical trials spanning multiple years and involving more than one hundred patients, we believe our approach can address the underlying cause of symptoms and liver damage. Our goal is to give families their lives back.

Pafford Medical Services

With one call, Pafford Medical Services facilitates every component of patient transport on both sides of the horizon.

Trevi Therapeutics

Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.